Telesis Bio (TBIO) Competitors $0.30 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TBIO vs. AXDX, SMIT, SPEC, THMO, HTGMQ, OLITW, PRENW, QSIAW, SMAPW, and TTShould you be buying Telesis Bio stock or one of its competitors? The main competitors of Telesis Bio include Accelerate Diagnostics (AXDX), Schmitt Industries (SMIT), Spectaire (SPEC), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), and Trane Technologies (TT). These companies are all part of the "measuring and control equipment" industry. Telesis Bio vs. Its Competitors Accelerate Diagnostics Schmitt Industries Spectaire ThermoGenesis HTG Molecular Diagnostics OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Telesis Bio (NASDAQ:TBIO) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends. Is TBIO or AXDX more profitable? Telesis Bio has a net margin of -336.59% compared to Accelerate Diagnostics' net margin of -471.83%. Company Net Margins Return on Equity Return on Assets Telesis Bio-336.59% N/A -61.89% Accelerate Diagnostics -471.83%N/A -191.66% Which has more volatility & risk, TBIO or AXDX? Telesis Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Accelerate Diagnostics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Do insiders and institutionals have more ownership in TBIO or AXDX? 37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 17.1% of Accelerate Diagnostics shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Comparatively, 43.6% of Accelerate Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to TBIO or AXDX? In the previous week, Accelerate Diagnostics' average media sentiment score of 0.95 beat Telesis Bio's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the news media. Company Overall Sentiment Telesis Bio Neutral Accelerate Diagnostics Positive Do analysts rate TBIO or AXDX? Given Accelerate Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Accelerate Diagnostics is more favorable than Telesis Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telesis Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Accelerate Diagnostics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has higher earnings & valuation, TBIO or AXDX? Telesis Bio has higher revenue and earnings than Accelerate Diagnostics. Telesis Bio is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelesis Bio$225.09M0.00-$47.72M-$28.20-0.01Accelerate Diagnostics$11.70M0.00-$61.62M-$2.34N/A SummaryTelesis Bio beats Accelerate Diagnostics on 7 of the 13 factors compared between the two stocks. Get Telesis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBIO vs. The Competition Export to ExcelMetricTelesis BioAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$541K$18.00M$5.62B$9.10BDividend YieldN/AN/A5.24%4.00%P/E Ratio-0.01N/A28.0520.27Price / Sales0.008.76429.5999.27Price / CashN/AN/A37.4658.16Price / Book2.140.828.055.49Net Income-$47.72M-$68.18M$3.18B$250.45M7 Day PerformanceN/A1.19%3.60%4.77%1 Month PerformanceN/A1.42%4.03%7.66%1 Year Performance-91.83%-15.27%29.49%16.39% Telesis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBIOTelesis BioN/A$0.30flatN/A-91.9%$541K$225.09M-0.01200Gap UpAXDXAccelerate Diagnostics1.1888 of 5 starsN/AN/AN/A$857K$11.70M-0.01220News CoverageGap DownHigh Trading VolumeSMITSchmitt IndustriesN/A$0.02flatN/AN/A$82K$9.89M0.00160SPECSpectaireN/A$0.00-81.8%N/A-100.0%$4KN/A0.008THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040HTGMQHTG Molecular DiagnosticsN/AN/AN/AN/A$0.00$6.37M0.0090OLITWOmniLit AcquisitionN/A$0.07-13.7%N/A-27.7%$0.00N/A0.003PRENWPrenetics GlobalN/A$0.05+15.4%N/A+96.0%$0.00$41.52M0.001Gap UpQSIAWQuantum-SiN/A$0.66-6.7%N/A+335.9%$0.00$3.44M0.00150SMAPWSportsMap Tech AcquisitionN/A$0.03flatN/AN/A$0.00N/A0.00N/ATTTrane Technologies4.4464 of 5 stars$434.11-0.7%$430.13-0.9%+26.9%$97.55B$19.84B36.1245,000Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Accelerate Diagnostics Competitors Schmitt Industries Competitors Spectaire Competitors ThermoGenesis Competitors HTG Molecular Diagnostics Competitors OmniLit Acquisition Competitors Prenetics Global Competitors Quantum-Si Competitors SportsMap Tech Acquisition Competitors Trane Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBIO) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
